These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 25816315

  • 1. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C, Jia J, Dong K, Luo L, Wu K, Mehta R, Peng J, Ren Y, Gross A, Yu H.
    PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
    [Abstract] [Full Text] [Related]

  • 2. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
    Kelleher DL, Mehta RS, Jean-Francois BM, Preece AF, Blowers J, Crater GD, Thomas P.
    PLoS One; 2012 Oct; 7(12):e50716. PubMed ID: 23284643
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
    Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A.
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):753-64. PubMed ID: 26227101
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.
    Li Y, Li H, Sheng Y, Du X, Yao Y, Luo X, Ma P.
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):721-733. PubMed ID: 30427594
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 10. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Mehta R, Green M, Patel B, Wagg J.
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):153-64. PubMed ID: 26739997
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J, Zhong N, Newlands A, Church A, Goh AH.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr; 10():1753-67. PubMed ID: 26366068
    [Abstract] [Full Text] [Related]

  • 12. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA.
    Clin Pharmacokinet; 2020 Jan; 59(1):67-79. PubMed ID: 31321713
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
    Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A.
    Respir Res; 2014 Jul 11; 15(1):78. PubMed ID: 25015176
    [Abstract] [Full Text] [Related]

  • 16. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R, Norris V, Siederer S.
    Pulm Pharmacol Ther; 2013 Apr 11; 26(2):256-64. PubMed ID: 23232038
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 11; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 20. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I.
    Int J Chron Obstruct Pulmon Dis; 2016 Aug 11; 11():1413-24. PubMed ID: 27445468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.